AstraZeneca is partnering with AI biotech insitro in a deal worth up to $1.5 billion

Insitro will get $40 million at signing and could collect as much as roughly $1.46 billion more if it reaches certain development and sales goals, AstraZeneca said. The agreement also provides for potential single-digit royalties on global commercial sales. Together, the payments put the deal's potential value at about $1.5 billion, according to The Wall Street Journal.

AstraZeneca will have sole global rights to carry forward any chosen programs that emerge from the collaboration. The collaboration is multi-year, according to Reuters.

Insitro will rely on its Virtual Human AI platform to pinpoint what drives each of the two diseases and to carry targets nominated by AstraZeneca from early discovery to a development candidate. Insitro, which announced the agreement separately, said AstraZeneca will take charge of every stage of human testing, regulatory submissions and bringing any resulting medicines to market.

AstraZeneca described MASH and cardiomyopathies as complex, heterogeneous diseases with significant unmet need.

"We know that disease biology is incredibly complex, and one of the most critical decisions in R&D is selecting the right target," Sharon Barr, AstraZeneca's executive vice president and head of BioPharmaceuticals R&D, said in a statement.

Barr also spoke about how the company picks targets. "By the time we read about a new pathway or target (in major scientific journals), it is no longer novel. It's in the public domain and we're already a few steps too late," she told Reuters. She added that when seasoned researchers work alongside AI tools, the company can screen fewer compounds at the bench, according to Reuters.

Daphne Koller, founder and CEO of Insitro, said in a statement that MASH and cardiomyopathies are prevalent, underdiagnosed diseases in which high-content data holds signal for uncovering disease drivers. She said the partnership pairs Insitro's biological precision with AstraZeneca's pharmaceutical expertise and scale.

Insitro has existing collaborations with Bristol Myers Squibb $BMY, Eli Lilly $LLY and Gilead $GILD, the company said.

AstraZeneca has had setbacks in both disease areas. Its drug Wainua failed to show benefit in a heart muscle disease trial this year, and the drugmaker ended development of a mid-stage MASH candidate last year.